Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Elaprase

Elaprase 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 5

HOS-115992 · Präparat HOS-094403

Adverse reactions are listed in table 1 with information presented by system organ class and frequency. Frequency is given as very common (≥ 1/10), common (≥ 1/100 to < 1/10) or uncommon (≥ 1/1 000 to < 1/100). The occurrence of an adverse reaction in a single patient is defined as common in view of the number of patients treated. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Adverse reactions only reported during the post marketing period are also included in the table with a frequency “not known” (cannot be estimated from the available data).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.